These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9089648)

  • 1. Eyeing up Graves' ophthalmopathy.
    Weetman AP
    Mol Cell Endocrinol; 1997 Feb; 126(2):113-6. PubMed ID: 9089648
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of Graves' disease and the course of ophthalmopathy.
    Sridama V; DeGroot LJ
    Am J Med; 1989 Jul; 87(1):70-3. PubMed ID: 2741983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgical management of Graves' ophthalmopathy.
    Austin MW; Atta HR
    Br J Hosp Med; 1992 Nov 18-Dec 1; 48(10):644-9. PubMed ID: 1458273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease.
    Noh JY; Hamada N; Inoue Y; Abe Y; Ito K; Ito K
    Thyroid; 2000 Sep; 10(9):809-13. PubMed ID: 11041459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy.
    Prummel MF; Wiersinga WM; Mourits MP; Koornneef L; Berghout A; van der Gaag R
    Arch Intern Med; 1990 May; 150(5):1098-101. PubMed ID: 1691908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis and treatment of the ophthalmopathy associated with Graves' disease.
    Velkeniers B; Salu P
    Bull Soc Belge Ophtalmol; 1992; 245():9-14. PubMed ID: 1344754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Graves' dermopathy and acropachy are markers of severe Graves' ophthalmopathy.
    Fatourechi V; Bartley GB; Eghbali-Fatourechi GZ; Powell CC; Ahmed DD; Garrity JA
    Thyroid; 2003 Dec; 13(12):1141-4. PubMed ID: 14751035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Graves' ophthalmopathy: search for shared autoantigen(s) continues.
    Bartalena L
    J Endocrinol Invest; 2005 May; 28(5):396-7. PubMed ID: 16075919
    [No Abstract]   [Full Text] [Related]  

  • 9. Extraocular muscle antibodies and the occurrence of ophthalmopathy in Graves' disease.
    de Bellis A; Perrino S; Coronella C; Sansone D; Ruocco G; Tirelli G; Di Martino S; Conte M; Bellastella G; Wall JR; Bellastella A; Bizzarro A
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):694-8. PubMed ID: 15163332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum antibodies against the flavoprotein subunit of succinate dehydrogenase are sensitive markers of eye muscle autoimmunity in patients with Graves' hyperthyroidism.
    Gunji K; De Bellis A; Kubota S; Swanson J; Wengrowicz S; Cochran B; Ackrell BA; Salvi M; Bellastella A; Bizzarro A; Sinisi AA; Wall JR
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1255-62. PubMed ID: 10199764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Graves' ophthalmopathy.
    Yeatts RP; Clontz DM
    J Ophthalmic Nurs Technol; 1990; 9(1):16-21. PubMed ID: 2313706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Graves' ophthalmopathy and dermopathy. Preface.
    Wiersinga WM
    Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):227. PubMed ID: 22632360
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum levels of soluble Fas in patients with Graves' ophthalmopathy.
    Ohtsuka K; Hashimoto M
    Br J Ophthalmol; 2000 Jan; 84(1):103-6. PubMed ID: 10611108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunologically mediated cytotoxicity against human eye muscle cells in Graves' ophthalmopathy.
    Wang PW; Hiromatsu Y; Laryea E; Wosu L; How J; Wall JR
    J Clin Endocrinol Metab; 1986 Aug; 63(2):316-22. PubMed ID: 3755139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toward better models of hyperthyroid Graves' disease.
    Dağdelen S; Kong YC; Banga JP
    Endocrinol Metab Clin North Am; 2009 Jun; 38(2):343-54, viii. PubMed ID: 19328415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenesis of Graves' ophthalmopathy--current understanding.
    Wiersinga WM; Prummel MF
    J Clin Endocrinol Metab; 2001 Feb; 86(2):501-3. PubMed ID: 11157999
    [No Abstract]   [Full Text] [Related]  

  • 17. The ophthalmopathy of Graves' disease.
    Carter JA; Utiger RD
    Annu Rev Med; 1992; 43():487-95. PubMed ID: 1580604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between Graves' ophthalmopathy and type of treatment of Graves' hyperthyroidism.
    Marcocci C; Bartalena L; Bogazzi F; Bruno-Bossio G; Pinchera A
    Thyroid; 1992; 2(2):171-8. PubMed ID: 1525588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical review 157: Pathophysiology of Graves' ophthalmopathy: the cycle of disease.
    Bahn RS
    J Clin Endocrinol Metab; 2003 May; 88(5):1939-46. PubMed ID: 12727937
    [No Abstract]   [Full Text] [Related]  

  • 20. Cloning and characterization of the novel thyroid and eye muscle shared protein G2s: autoantibodies against G2s are closely associated with ophthalmopathy in patients with Graves' hyperthyroidism.
    Gunji K; De Bellis A; Li AW; Yamada M; Kubota S; Ackrell B; Wengrowicz S; Bellastella A; Bizzarro A; Sinisi A; Wall JR
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1641-7. PubMed ID: 10770210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.